HOTAIR Facilitates Endocrine Resistance in Breast Cancer Through ESR1/miR-130b-3p Axis: Comprehensive Analysis of mRNA-miRNA-lncRNA Network

References

• DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–451. doi:10.3322/caac.21583
   PubMed Web of Science ®Google Scholar
• Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst. 1998;90(11):814–823. doi:10.1093/jnci/90.11.814
   PubMed Web of Science ®Google Scholar
• McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science. 2002;296(5573):1642–1644. doi:10.1126/science.1071884
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–643. doi:10.1038/nrc2713
   PubMed Web of Science ®Google Scholar
• Najim O, Seghers S, Sergoynne L, et al. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: a systematic review and meta-analysis of randomized and non-randomized trials. Biochim Biophys Acta Rev Cancer. 2019;1872(2):188315. doi:10.1016/j.bbcan.2019.188315
   PubMed Web of Science ®Google Scholar
• Haque MM, Desai KV. Pathways to endocrine therapy resistance in breast cancer. Front Endocrinol (Lausanne). 2019;10:573. doi:10.3389/fendo.2019.00573
   PubMed Web of Science ®Google Scholar
• Fu XD. Non-coding RNA: a new frontier in regulatory biology. Natl Sci Rev. 2014;1(2):190–204. doi:10.1093/nsr/nwu008
   PubMed Web of Science ®Google Scholar
• Gao L, Li X, Nie X, et al. Construction of novel mRNA-miRNA-lncRNA regulatory networks associated with prognosis of ovarian cancer. J Cancer. 2020;11(23):7057–7072. doi:10.7150/jca.49557
   PubMed Web of Science ®Google Scholar
• Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta stone of a hidden RNA language? Cell. 2011;146(3):353–358. doi:10.1016/j.cell.2011.07.014
   PubMed Web of Science ®Google Scholar
• Lu C, Luo X, Xing C, et al. Construction of a novel mRNA-miRNA-lncRNA network and identification of potential regulatory axis associated with prognosis in colorectal cancer liver metastases. Aging. 2021;13(11):14968–14988. doi:10.18632/aging.203049
   PubMedGoogle Scholar
• Hu B, Ma X, Fu P, et al. miRNA-mRNA regulatory network and factors associated with prediction of prognosis in hepatocellular carcinoma. Genomics Proteomics Bioinformatics. 2021:S1672-0229(21)00059-0. doi:10.1016/j.gpb.2021.03.001
   Web of Science ®Google Scholar
• Landeros N, Santoro PM, Carrasco-Avino G, Corvalan AH. Competing endogenous RNA networks in the epithelial to mesenchymal transition in diffuse-type of gastric cancer. Cancers. 2020;12(10):10. doi:10.3390/cancers12102741
   Web of Science ®Google Scholar
• Chen X, Xu J, Zeng F, et al. Inferring cell subtypes and LncRNA function by a cell-specific ceRNA network in breast cancer. Front Oncol. 2021;11:656675. doi:10.3389/fonc.2021.656675
   PubMed Web of Science ®Google Scholar
• Garcia-Becerra R, Santos N, Diaz L, Camacho J. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci. 2012;14(1):108–145. doi:10.3390/ijms14010108
   PubMed Web of Science ®Google Scholar
• Muluhngwi P, Klinge CM. Roles for miRNAs in endocrine resistance in breast cancer. Endocr Relat Cancer. 2015;22(5):R279–R300. doi:10.1530/ERC-15-0355
   PubMed Web of Science ®Google Scholar
• Zhou J, Teng R, Wang Q, et al. Endocrine resistance in breast cancer: current status and a perspective on the roles of miRNAs. Oncol Lett. 2013;6(2):295–305. doi:10.3892/ol.2013.1405
   PubMed Web of Science ®Google Scholar
• Hayes EL, Lewis-Wambi JS. Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA. Breast Cancer Res. 2015;17(1):40. doi:10.1186/s13058-015-0542-y
   PubMed Web of Science ®Google Scholar
• van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 2015;17(1):21. doi:10.1186/s13058-015-0526-y
   PubMed Web of Science ®Google Scholar
• Godinho MF, Sieuwerts AM, Look MP, et al. Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. Br J Cancer. 2010;103(8):1284–1291. doi:10.1038/sj.bjc.6605884
   PubMed Web of Science ®Google Scholar
• Meijer D, van Agthoven T, Bosma PT, Nooter K, Dorssers LC. Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol Cancer Res. 2006;4(6):379–386. doi:10.1158/1541-7786.MCR-05-0156
   PubMed Web of Science ®Google Scholar
• Chen H, Yang Y, Wang J, Shen D, Zhao J, Yu Q. miR-130b-5p promotes proliferation, migration and invasion of gastric cancer cells via targeting RASAL1. Oncol Lett. 2018;15(5):6361–6367.
   PubMed Web of Science ®Google Scholar
• Liu X, Kong C, Zhang Z. miR-130b promotes bladder cancer cell proliferation, migration and invasion by targeting VGLL4. Oncol Rep. 2018;39(5):2324–2332.
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Shiina M, Dasgupta P, et al. Upregulation of miR-130b contributes to risk of poor prognosis and racial disparity in African-American prostate cancer. Cancer Prev Res. 2019;12(9):585–598. doi:10.1158/1940-6207.CAPR-18-0509
   PubMed Web of Science ®Google Scholar
• Mu HQ, He YH, Wang SB, et al. MiR-130b/TNF-alpha/NF-kappaB/VEGFA loop inhibits prostate cancer angiogenesis. Clin Transl Oncol. 2020;22(1):111–121. doi:10.1007/s12094-019-02217-5
   PubMed Web of Science ®Google Scholar
• Yu DJ, Zhong M, Wang WL. Long noncoding RNA CASC15 is upregulated in non-small cell lung cancer and facilitates cell proliferation and metastasis via targeting miR-130b-3p. Eur Rev Med Pharmacol Sci. 2019;23(18):7943–7949.
   PubMed Web of Science ®Google Scholar
• Yang C, Cai J, Wang Q, et al. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol. 2012;124(2):325–334. doi:10.1016/j.ygyno.2011.10.013
   PubMed Web of Science ®Google Scholar
• Mozdarani H, Ezzatizadeh V, Rahbar Parvaneh R. The emerging role of the long non-coding RNA HOTAIR in breast cancer development and treatment. J Transl Med. 2020;18(1):152. doi:10.1186/s12967-020-02320-0
   PubMed Web of Science ®Google Scholar
• Xu S, Kong D, Chen Q, Ping Y, Pang D. Oncogenic long noncoding RNA landscape in breast cancer. Mol Cancer. 2017;16(1):129. doi:10.1186/s12943-017-0696-6
   PubMed Web of Science ®Google Scholar
• Pawlowska E, Szczepanska J, Blasiak J. The long noncoding RNA HOTAIR in breast cancer: does autophagy play a role? Int J Mol Sci. 2017;18(11):11. doi:10.3390/ijms18112317
   Web of Science ®Google Scholar
• Xue X, Yang YA, Zhang A, et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 2016;35(21):2746–2755. doi:10.1038/onc.2015.340
   PubMed Web of Science ®Google Scholar
• Nedeljkovic M, Tanic N, Prvanovic M, Milovanovic Z, Tanic N. Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer. Breast Cancer. 2021;28(3):727–736. doi:10.1007/s12282-020-01210-z
   PubMed Web of Science ®Google Scholar
• Liao M, Wang C, Yang B, et al. Autophagy blockade by Ai Du Qing formula promotes chemosensitivity of breast cancer stem cells via GRP78/beta-catenin/ABCG2 axis. Front Pharmacol. 2021;12:659297. doi:10.3389/fphar.2021.659297
   PubMed Web of Science ®Google Scholar
• Busby M, Hallett MT, Plante I. The complex subtype-dependent role of connexin 43 (GJA1) in breast cancer. Int J Mol Sci. 2018;19(3):693. doi:10.3390/ijms19030693
   PubMed Web of Science ®Google Scholar
• Phillips SL, Williams CB, Zambrano JN, Williams CJ, Yeh ES. Connexin 43 in the development and progression of breast cancer: what’s the connection?. Int J Oncol. 2017;51(4):1005–1013. doi:10.3892/ijo.2017.4114
   PubMed Web of Science ®Google Scholar